Use of CpG oligodeoxynucleotides as immunoprotective agents

Bibliography

• EFFROS RB, WALFORD RL: Diminished T cell response to influenza virus in aged mice. Immunology (1983) 49:387–393.
   PubMed Web of Science ®Google Scholar
• PAGANELLI R, SCALA E, QUINTI I, ANSOTEGUI IJ: Humoral immunity in aging. Ageing Clin. Exp. Res. (1994) 6:143–150.
   Web of Science ®Google Scholar
• CORBETT EL, STEKETEE RW, TER KUILE FO, LATIF AS, KAMALI A, HAYES RJ: HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet (2002) 359:2177–2187.
   PubMed Web of Science ®Google Scholar
• WEINBERG ED: Pregnancy-associated depression of cell-mediated immunity. Rev Lifect. Dis. (1984) 6:814–831.
   PubMedGoogle Scholar
• MARRACK P, KAPPLER J: Subversion of the immune system by pathogens. Cell (1994) 76:323–332.
   PubMed Web of Science ®Google Scholar
• MEDZHITOV R, JANE WAY CA: Innate immunity: impact on the adaptive immune response. Cud: Opin. kninunol. (1997) 9:4–9.
   PubMed Web of Science ®Google Scholar
• MEDZHITOV R, JANE WAY CA: Innate immunity: the virtues of a nonclonal system of recognition. Cell (1998) 91:295–298.
   Web of Science ®Google Scholar
• UNDERHILL DM, OZINSKY A: Toll-like receptors: key mediators of microbe detection. Cud: Opin. kninunol. (2002) 14:103–110.
   PubMed Web of Science ®Google Scholar
• VASSELON T, DETMERS PA: Toll receptors: a central element in innate immune responses. Infect. Inman. (2002) 70:1033–1041.
   PubMed Web of Science ®Google Scholar
• RAZIN A, FRIEDMAN J: DNA methylation and its possible biological roles. Frog. Nucleic Add Res. Mol. Biol. (1981) 25:33–52.
   PubMedGoogle Scholar
• CARDON LR, BURGE C, CLAYTON DA, KARLIN S: Pervasive CpG suppression in animal mitochondrial genomes. Proc. Natl. Acad. Sci. USA (1994) 91:3799–3803.
   PubMed Web of Science ®Google Scholar
• WAGNER H: Bacterial CpG-DNA activatesimmune cells to signal 'infectious danger'. Adv. Inonunol. (1999) 73:329–368.
   PubMed Web of Science ®Google Scholar
• KLINMAN DM, VERTHELYI D, TAKESHITA F, ISHII KJ: Immune recognition of foreign DNA: a cure for bioterrorism? Immunity (1999) 11:123–129.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO S, KATOAKA T, YANO 0, KURAMOTO E, SHIMADA S, TOKUNAGA T: Antitumor effect of nucleic acid fraction from bacteria. Proc. fpn. Soc. kninunol. (1989) 48:272–281.
   Google Scholar
• •Early paper describing the irnmunomodulatory effects of bacterial DNA.
   Google Scholar
• YAMAMOTO S, YAMAMOTO T, KATOAKA T, KURAMOTO E, YANO 0, TOKUNAGA T: Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. I Inonunol. (1992) 148:4072–4076.
   Google Scholar
• KRIEG AM, YI A, MATSON S et aL: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 374:546–548.
   PubMed Web of Science ®Google Scholar
• ••Original paper describing the irnmunostintulatory activity of CpG motifs that demonstrated their ability to activate B cells.
   Google Scholar
• KLINMAN DM, YI A, BEAUCAGE SL, CONOVER J, KRIEG AM: CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFNgamma. Proc. Natl. Acad. Sci. USA (1996) 93:2879–2883.
   PubMed Web of Science ®Google Scholar
• ••Original paper to describe the ability of CpG motifs to induce Thl and pro-inflammatory cytokine production.
   Google Scholar
• TAKESHITA F, LEIFER CA, GURSEL I et al: Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. kninunol. (2001) 167:3555–3558.
   Google Scholar
• •Establishes that human cells use TLR9 to detect CpG DNA.
   Google Scholar
• HEMMI H, TAKEUCHI 0, KAWAI T et al.: A Toll-like receptor recognizes bacterial DNA. Nature (2000) 408:740–745.
   Google Scholar
• ••Identifies TLR9 as the receptor forCpG DNA.
   Google Scholar
• BAUER S, KIRSCHNING CJ, HACKER H et al.: Human TLR9 confers responsiveness to bacterial DNA via species - specific CpG motif recognition. Proc. Nati Acad. Sci. USA (2001) 98:9237–9242.
   PubMed Web of Science ®Google Scholar
• GURSEL M, VERTHELYI D, GURSEL I, ISHII KJ, KLINMAN DM: Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotides. Leukoc. Biol. (2002) 71:813–820.
   PubMed Web of Science ®Google Scholar
• HORNUNG V, ROTHENFUSSER S, BRITSCH S et al.: Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. kninunol. (2002) 168:4531–4537.
   Google Scholar
• HAYASHI F, MEANS TK, LUSTER AD: Toll-like receptors stimulate human neutrophil function. Blood (2003) 102:2660–2669.
   PubMed Web of Science ®Google Scholar
• BAUER M, REDECKE V, ELLWART JW et al.: Bacterial CpG DNA triggers activation and maturation of human CD11c(-), CD123(+) dendritic cells. .1. Immunol (2001) 166:5000–5007.
   Google Scholar
• BAUER M, HEEG K, WAGNER H, LIPFORD GB: DNA activates human immune cells through a CpG sequence-dependent manner. Immunology (1999) 97:699–705.
   PubMed Web of Science ®Google Scholar
• AURICCHIO G, GARG SK, MARTINO A et al.: Role of macrophage phospholipase D in natural and CpG-induced antimycobacterial activity. Cell Microbiol (2003) 5:913–920.
   PubMed Web of Science ®Google Scholar
• SUN S, ZHANG X, TOUGH DF, SPRENT J: Type I interferon-mediated stimulation of T cells by CpG DNA. I Exp. Med. (1998) 188:2335–2342.
   PubMed Web of Science ®Google Scholar
• STACEY KJ, SWEET MJ, HUME DA: Macrophages ingest and are activated by bacterial DNA. Immunol (1996) 157:2116–2120.
   Web of Science ®Google Scholar
• IHO S, YAMAMOTO T, TAKAHASHI T, YAMAMOTO S: Oligodeoidnucleotides containing palindrome sequences with internal 5'CpG-3' act directly on human NK and activated T cells to induce IFN-gamma production M vitro.' Immunol (1999) 163:3642–3652.
   Web of Science ®Google Scholar
• ROMAN M, MARTIN-OROZCO E, GOODMAN JS et al: Immunostimulatory DNA sequences function as T helper-1 promoting adjuvants. Nat. Med. (1997) 3:849–854.
   PubMed Web of Science ®Google Scholar
• ••Original paper describing the contributionof CpG motifs to the immune stimulation induced by DNA vaccines.
   Google Scholar
• BALLAS ZD, RASMUSSEN WL, KRIEG AM: Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. .1. Immunol (1996) 157:1840–1847.
   PubMed Web of Science ®Google Scholar
• HALPERN MD, KURLANDER RJ, PISETSKY DS: Bacterial DNA induces murine interferon-gamma production by stimulation of IL-12 and tumor necrosis factor-alpha. Cell. Immunol (1996) 167:72–78.
   PubMed Web of Science ®Google Scholar
• WEIGHARDT H, FETEROWSKI C, VEIT M, RUMP M, WAGNER H, HOLZMANN B: Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. Immunol (2000) 165:4537–4543.
   Web of Science ®Google Scholar
• KANELLOS TS, SYLVESTER ID, BUTLER VL et al.: Mammalian granulocyte-macrophage colony stimulating factor and some CpG motifs have an effect on the immunogenicity of DNA and subunit vaccines in fish. Immunology (1999) 96:507–510.
   PubMed Web of Science ®Google Scholar
• GOMIS S, BABIUK L, GODSON DL et al: Protection of chickens against Escherichia coli infections by DNA containing CpG motifs. Infect. Immun. (2003) 71:857–863.
   PubMed Web of Science ®Google Scholar
• RANKIN R, PONTAROLLO R, IOANNOU X et al: CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. (2001) 11:333–340.
   PubMedGoogle Scholar
• •Establishes that multiple species respond to CpG DNA.
   Google Scholar
• ZIMMERMANN S, EGETER 0, HAUSMANN S et al.: CpG oligodeoxynucleotides trigger protective and curative Thl responses in lethal murine Leishmaniasis. Immunol (1998) 160:3627–3630.
   Google Scholar
• •Established that the innate immune response elicited by CpG DNA was immunoprotective.
   Google Scholar
• HEINZEL FP, SADICK MD, JOLADAY BJ, COFFMAN RL, LOCKSLEY RM: Reciprocal expression of IFNgamma or IL-4 during the resolution or progression of murine leishmaniasis.J. Exp. Med. (1989) 169:59–72.
   PubMed Web of Science ®Google Scholar
• KRIEG AM, HOMAN LL, YI AK, HARTY JT: CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. Immunol (1998) 161:2428–2434.
   Web of Science ®Google Scholar
• KLINMAN DM: Therapeutic applications of CpG-containing oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev. (1998) 8:181–184.
   PubMedGoogle Scholar
• ELKINS KL, RHINEHART-JONES TR, STIBITZ S, CONOVER JS, KLINMAN DM: Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. Immunol (1999) 162:2291–2298.
   Web of Science ®Google Scholar
• ISHII KJ, ITO S, CON OVER J et al.: CpG-activated plasmacytoid dendritic cells protect against lethal Listeria monocytogenes infection. Immunol (2004) (In Press).
   Google Scholar
• •Identified the critical role of pDCs in CpG-mediated protection.
   Google Scholar
• BROIDE DH, STACHNICK G, CASTANEDA D et al.: Systemic administration of immunostimulatory DNA sequences mediates reversible inhibition of Th2 responses in a mouse model of asthma. J. Clin. Immunol (2001) 21:175–182.
   PubMedGoogle Scholar
• MARSHALL JD, FEARON K, ABBATE Cet al.: Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. Leukoc. Biol. (2003) 73:781–792.
   Google Scholar
• VERTHELYI D, KENNEY RT, SEDER RA, GAM AA, FRIEDAG B, KLINMAN DM: CpG oligodeoxynucleotides as vaccine adjuvants in primates. I Immunol (2002) 168:1659–1663.
   PubMed Web of Science ®Google Scholar
• DAVIS HL, SUPARTO II, WEERATNA RR et al.: CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine (2000) 18:1920–1924.
   PubMed Web of Science ®Google Scholar
• ••Established the in vivo activity ofCpG ODNs as vaccine adjuvants in non-human primates.
   Google Scholar
• VERTHELYI D, KLINMAN DM: Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin. Immunol (2003) 109:64–71.
   PubMed Web of Science ®Google Scholar
• DONG L, MORI I, HOSSAIN MI, LIU B, KIMURA Y: An immunostimulatory oligodeoxynucleotide containing a cytidine-guanosine motif protects senescence-accelerated mice from lethal influenza virus by augmenting the T helper type 1 response. I Gen. Viral. (2003) 84:1623–1628.
   PubMed Web of Science ®Google Scholar
• OLBRICH AR, SCHIMMER S, HEEG K, SCHEPERS K, SCHUMACHER TN, DITTMER U: Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs.Viral. (2002) 76:11397–11404.
   PubMed Web of Science ®Google Scholar
• HARANDI AM, ERIKSSON K, HOLMGREN J: A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. I Viral. (2003) 77:953–962.
   PubMed Web of Science ®Google Scholar
• VERTHELYI D, GURSEL M, KENNEY RT et al: CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. Immunol. (2003) 170:4717–4723.
   Web of Science ®Google Scholar
• •Established that CpG ODNs were active in immunosuppressed primates.
   Google Scholar
• AMARAL VF, RANSATTO VAO, CONCEICAO-SOLVA F et al.: Leishmania arnazonensis: the asian rhesus macaques (Macaca mulata) as an experimental model for the study of cutaneous leishmaniasis. Exp. Parasitol (1996) 82:34–44.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO S, YAMAMOTO T, TOKUNAGA T: Oligodeoxyribonucleotides with 5'-ACGT-3' or 5'TCGA-3' sequence induce production of interferons. Carr. Top. Microbiol. Immunol. (2000) 247:23–40.
   PubMed Web of Science ®Google Scholar
• OLBRICH AR, SCHIMMER S, DITTMER U: Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemia.Virol. (2003) 77:10658–10662.
   Web of Science ®Google Scholar
• ASHKAR AA, BAUER S, MITCHELL WJ, VIEIRA J, ROSENTHAL KL: Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. Virol. (2003) 77:8948–8956.
   Web of Science ®Google Scholar
• PACANOWSKI J, KAHI S, BAILLET M et al: Reduced blood CD123+ (lymphoid) and CD1 lc+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood (2001) 98:3016–3021.
   PubMed Web of Science ®Google Scholar
• CHEHIMI J, CAMPBELL DE, AZZONI L et al: Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. Immunol. (2002) 168:4796–4801.
   Web of Science ®Google Scholar
• PRIDDY KD: Immunologic adaptations during pregnancy. I. Obstet. Gynecol Neonatal Nurs. (1997) 26:388–394.
   PubMedGoogle Scholar
• WEGMANN TG, LIN H, GUILBERT L, MOSMANN TR: Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol. Today (1993) 14:353–356.
   Google Scholar
• LIN H, MOSMANN TR, GUILBERT L, TUNTIPOPIPAT S, WEGMANN TG: Synthesis of T helper 2-type cytokines at the maternal-fetal interface.' Immunol. (1993) 151:4562–4573.
   Web of Science ®Google Scholar
• RAGHUPATHY R: Thl-type immunity isincompatible with successful pregnancy. Immunol. Today(1997) 18:478–482.
   PubMedGoogle Scholar
• SANO M, MITSUYAMA M, WATANABE Y, NOMOTO K: Impairment of T cell-mediated immunity to Listeria monocytogenes in pregnant mice. Microbiol Immunol. (1986) 30:165–176.
   PubMed Web of Science ®Google Scholar
• KRISHNAN L, GUILBERT LJ, RUSSELL AS, WEGMANN TG, MOSMANN TR, BELOSEVIC M: Pregnancy impairs resistance of C57BL/6 mice to Leishmania nmjorinfection and causes decreased antigen-specific IFN-gamma response and increased production of T helper 2 cytokines. Immunol. (1996) 156:644–652.
   Web of Science ®Google Scholar
• ITO S, ISHII K, SHIROT H, KLINMAN DM: CpG Oligodeoxynucleotides improve the survival of pregnant and fetal mice following Listeria monocytogenes infection. Vaccine (2004) 72(6):3543–3548.
   Google Scholar
• KLINMAN DM, CONOVER J,COBAN C: Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect. Immun. (1999) 67:5658–5663.
   PubMed Web of Science ®Google Scholar
• GURSEL I, GURSEL M, ISHII KJ, KLINMAN DM: Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides.J. Immunol. (2001) 167:3324–3328.
   PubMed Web of Science ®Google Scholar
• GILKESON GS, RIUZ P, HOWELL D, LEFKOWITH JB, PISETSKY DS: Induction of immune-mediated glomerulonephritis in normal mice immunized with bacterial DNA. Clin. Immunol Immunopathol. (1993) 68:283–292.
   PubMedGoogle Scholar
• GILKESON GS, PIPPEN AM, PISETSKY DS: Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA. Clin. Invest. (1995) 95:1398–1402.
   Google Scholar
• STEINBERG AD, KRIEG AM, GOURLEY MF, KLINMAN DM: Theoretical and experimental approaches to generalized autoimmunity. Immunol. Rev. (1990) 118:129–163.
   PubMed Web of Science ®Google Scholar
• KLINMAN DM: Polyclonal B cell activation in lupus-prone mice precedes and predicts the development of autoimmune disease. Clin. Invest. (1990) 86:1249–1254.
   Google Scholar
• LINKER-ISRAELI M, DEANS R, WALLACE D, PREHN J, OZERI-CHEN T, KLINENBERG J: Elevated levels of endogenous IL-6 in systemic lupus erythematosus. Immunol (1991) 147:117–123.
   Web of Science ®Google Scholar
• KRIEG AM: CpG DNA : A pathogenic factor in systemic lupus erythematosus? Clin. Immunol. (1995) 15:284–292.
   Web of Science ®Google Scholar
• YI A-K, HORNBECK P, LAFRENZ DE, KRIEG AM: CpG DNA rescue of murine B lymphoma cells from anti-IgM induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xl. Immunol. (1996) 157:4918–4925.
   Web of Science ®Google Scholar
• MOR G, SINGLA M, STEINBERG AD, HOFFMAN SL, OKUDA K, KLINMAN DM: Do DNA vaccines induce autoimmune disease? Hum. Gene Ther. (1997) 8:293–300.
   Web of Science ®Google Scholar
• KATSUMI A, EMI N, ABE A, HASEGAWA Y, ITO M, SAITO H: Humoral and cellular immunity to an encoded protein induced by direct DNA injection. Hum. Gene Ther. (1994) 5:1335–1339.
   PubMed Web of Science ®Google Scholar
• GILKESON GS, CONOVER JS, HALPERN M, PISETSKY DS, FEAGIN A, KLINMAN DM: Effects of bacterial DNA on cytokine production by (NZB/NZW) Fl mice. j Immunol (1998) 161:3890–3895.
   PubMed Web of Science ®Google Scholar
• HASEGAWA K, HAYASHI T: Synthetic CpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB x NZWF1 mice. Lupus (2003) 12:838–845.
   PubMed Web of Science ®Google Scholar
• SE GAL BM, KLINMAN DM, SHE VACH EM: Microbial products induce autoimmune disease by an IL-12 dependent process. Immunol (1997) 158:5087–5091.
   Web of Science ®Google Scholar
• SEGAL BM, CHANG JT, SHEVACH EM:CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalotogenic T cells M vivo. Immunol. (2000) 164:5683–5688.
   Web of Science ®Google Scholar
• SHAO H, LEI S, SUN SL, KAPLAN HJ, SUN D: Conversion of monophasic to recurrent autoimmune disease by autoreactive T cell subsets. J. Immunol. (2003) 171:5624–5630.
   PubMed Web of Science ®Google Scholar
• ZEUNER RA, VERTHELYI D, GURSEL M, ISHII KJ, KLINMAN DM: Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis. Arthritic Rheum. (2003) 48:1701–1707.
   PubMed Web of Science ®Google Scholar
• KASER A, TILG H: Interferon-alpha in inflammation and immunity. Cell. Mol. Biol. (2001) 47:609–617.
   PubMed Web of Science ®Google Scholar
• BACHMAIER K, MEU N, MAZA LM, PALS, NESSEL A, PENNINGERJM: Chlamydia infections and heart disease linked through antigenic mimicry. Science (1999) 283:1335–1339.
   PubMed Web of Science ®Google Scholar
• SPARWASSER T, MEITHKE T, LIPFORD G et al.: Bacterial DNA causes septic shock. Nature (1997) 386:336–338.
   PubMed Web of Science ®Google Scholar
• COWDERY JS, CHACE JH, YI A-K, KRIEG AM: Bacterial DNA induces NK cells to produce IFNgamma in vivo and increases the toxicity of lipopolysaccharides. .1 Immunol. (1996) 156:4570–4575.
   Google Scholar
• HARTMANN G, KRUG A, WALLER K, ENDRES S: Oligodeoxynucleotides enhance LPS-stimulated synthesis of TNF: dependence on phosphorothioate modification and reversal by heparin. Mol. Med. (1996) 2:429–438.
   PubMed Web of Science ®Google Scholar
• HEIKENWALDER M, POLYMENIDOU M, JUNT T et al.: Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. (2004) 10:187–192.
   PubMed Web of Science ®Google Scholar
• KLINMAN DM, TAKENO M, ICHINO M et al.: DNA vaccines: safety and efficacy issues. Springer Semin. Immunopathol. (1997) 19:245–256.
   PubMed Web of Science ®Google Scholar
• YACYSHYN BR, BARISH C, GOFF J et al: Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment. Pharmacol. Ther. (2002) 16:1761–1770.
   PubMed Web of Science ®Google Scholar
• LIU MA: DNA vaccines: a review. 1 Intern.Med. (2003) 253:402–410.
   Google Scholar
• SETHI S, LIPFORD G, WAGNER H, KRETZSCHMAR H: Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet (2002) 360:229–230.
   PubMed Web of Science ®Google Scholar
• HALPERIN SA, VAN NEST G, SMITH B, ABTAHI S, WHILEY H, EIDEN JJ: A Phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine (2003) 21:2461–2467.
   PubMed Web of Science ®Google Scholar
• WANG R, DOOLAN DL, LE TP et al: Induction of antigen specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science (1998) 282:476–480.
   PubMed Web of Science ®Google Scholar
• JUFFERMANS NP, LEEMANS JC, FLORQUIN S et al.: CpG oligodeoxynucleotides enhance host defense during murine tuberculosis. Infect. Immun. (2002) 70:147–152.
   PubMed Web of Science ®Google Scholar
• WALKER PS, SCHARTON-KERSTEN T,KRIEG AM et al.: Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12 and IFNg dependent mechanisms. Proc. Natl. Acad. Sci. USA (1999) 96:6970–6975.
   Google Scholar
• GRAMZINSKI RA, DOOLAN DL, SEDEGAH M, DAVIS HL, KRIEG AM, HOFFMAN SL: Interleuldn-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect. Immun. (2001) 69:1643–1649.
   PubMed Web of Science ®Google Scholar
• JORGENSEN JB, JOHANSEN LH, STEIRO K, JOHANSEN A: CpG DNA induces protective antiviral immune responses in Atlantic salmon (Salmo salarL.). J. Virol. (2003) 77:11471–11479.
   PubMed Web of Science ®Google Scholar